Waldenstrom macroglobulinemia

Article written and reviewed by Dr Luca Moretti

Waldenstrom macroglobulinemia is a rare, low-grade lymphoplasmacytic neoplasm characterized by monoclonal proliferation of mature B cells with an intermediate differentiation between lymphocyte and plasma cell, resulting in excessive production of monoclonal immunoglobulin M (IgM). This particular form of monoclonal gammopathy belongs to the spectrum of chronic lymphoid neoplasms and is classified by the World Health Organization among indolent non-Hodgkin lymphomas.

The clinical picture of Waldenstrom macroglobulinemia is dominated by the presence of a high-molecular-weight serum IgM component, which causes both direct systemic manifestations (hyperviscosity syndrome, autoimmune phenomena, cryoglobulinemia) and indirect manifestations related to infiltration of the bone marrow, lymph nodes and, occasionally, the spleen or other organs. Diagnosis and management require a multidisciplinary approach that integrates the most recent molecular knowledge with careful clinical assessment of the marked heterogeneity of manifestations and patterns of progression.

Waldenstrom macroglobulinemia is clearly distinct from multiple myeloma and other monoclonal gammopathies in both cellular origin and clinical behavior, and it represents a paradigmatic chronic hematologic neoplasm in which understanding the biologic basis of disease and individualizing treatment are essential to improve prognosis and quality of life.

Etiology, pathogenesis and pathophysiology

The etiology of Waldenstrom macroglobulinemia remains largely unknown and is the subject of intensive clinical and experimental research. No universally accepted direct causal factors have been identified: disease onset appears to depend on a complex interaction among individual genetic predisposition, acquired molecular abnormalities and environmental stimuli whose nature remains unclear.

Despite the absence of an identifiable etiologic agent, several risk factors have been documented in epidemiologic studies. A higher incidence is observed in men, older individuals and patients with a positive family history of monoclonal gammopathies or lymphoproliferative neoplasms. Associations with environmental exposure to toxic substances (organic solvents, pesticides), chronic infections (particularly hepatitis C virus and HIV) and immunodeficiency states have also been reported inconsistently, although these factors have no predictive value in routine clinical practice.

From a pathogenetic standpoint, Waldenstrom macroglobulinemia originates from the neoplastic transformation of a mature B cell, generally at the post-germinal-center lymphocyte stage, which undergoes partial differentiation toward a plasma cell. These cells retain the ability to produce immunoglobulins but, unlike the mature plasma cells of multiple myeloma, characteristically produce monoclonal IgM, a high-molecular-weight immunoglobulin responsible for many of the disease-specific clinical manifestations.

Molecular advances in recent years have identified recurrent abnormalities. The MYD88 L265P mutation, present in the great majority of cases, activates pro-survival signaling pathways. CXCR4 mutations can modulate migration, homing and drug sensitivity of the clone. Other cytogenetic abnormalities contribute to biologic heterogeneity.

The pathophysiology of Waldenstrom macroglobulinemia reflects the distinctive features of the lymphoplasmacytic clone and of the IgM component produced in excess. Progressive bone marrow infiltration by neoplastic cells reduces normal hematopoiesis, causing normocytic anemia and, in more advanced cases, thrombocytopenia or leukopenia. Lymph node and splenic involvement may lead to clinically significant lymphadenopathy and splenomegaly, although these findings are often asymptomatic.

The synthesis of monoclonal IgM underlies hyperviscosity and may mediate autoantibody phenomena, neuropathies and cryoglobulinemia. Amyloidosis associated with Waldenstrom macroglobulinemia is generally of the AL type and is caused by amyloidogenic light chains produced by the clone, not by deposition of intact IgM.

Finally, the disease shows marked heterogeneity in its evolution: in some patients proliferation remains indolent and confined to the bone marrow for years, whereas others experience more rapid progression, with multiorgan involvement, marked increase in the IgM component and a greater risk of systemic complications.

Clinical manifestations

The clinical picture of Waldenstrom macroglobulinemia is notably heterogeneous and reflects the dual nature of the disease, resulting both from bone marrow and lymph node infiltration by the lymphoplasmacytic clone and from systemic effects mediated by excess circulating monoclonal IgM. Presentation may range from asymptomatic forms detected incidentally during routine testing to complex clinical syndromes with acute and potentially severe manifestations at onset.

In the initial phase, many patients are completely asymptomatic or report nonspecific symptoms such as asthenia, easy fatigability or modest weight loss. A careful history may reveal recurrent infections, epistaxis, gingival bleeding or mild bleeding abnormalities related to progressive reduction of normal hematopoietic lineages and IgM-induced platelet dysfunction.

The most frequent clinical finding is normocytic anemia, often insidious, accompanied by mucocutaneous pallor, exertional dyspnea, tachycardia and reduced exercise tolerance. In more advanced cases, cytopenia may also involve platelets, with bruising, petechiae and mucosal bleeding, and leukocytes, with predisposition to bacterial and viral infections. Lymph node infiltration causes superficial or deep, generally painless lymphadenopathy, while splenomegaly, when present, may cause a sensation of fullness or discomfort in the left upper quadrant.

A characteristic but not pathognomonic manifestation is serum hyperviscosity syndrome, present in a minority of patients and related mainly to the concentration and properties of monoclonal IgM. The syndrome develops insidiously, with neuro-ocular symptoms such as headache, dizziness, tinnitus, visual disturbances, diplopia, drowsiness and confusion, which in extreme cases may progress rapidly to cerebral ischemia, seizures or coma. Ocular hyperviscosity retinopathy may cause blurred vision, retinal hemorrhages, retinal detachment and vascular changes visible on funduscopic examination. Spontaneous bleeding manifestations, including epistaxis, gingival bleeding, menorrhagia and hematuria, are not uncommon and result from both impaired platelet function and obstructed flow in small vessels.

In a substantial proportion of patients, the autoantibody activity of monoclonal IgM is responsible for distinctive syndromes, including cold-antibody hemolysis, with hemolytic anemia, jaundice, splenomegaly and Raynaud attacks triggered by cold exposure, and sensorimotor peripheral neuropathy, presenting with paresthesias, distal sensory loss, progressive muscle weakness and, in more advanced cases, impaired walking. Neuropathy is often insidious and may precede the hematologic diagnosis by years, creating substantial differential diagnostic challenges with other immune-mediated neuropathies.

Other clinical manifestations include type I monoclonal cryoglobulinemia, with Raynaud phenomenon, purpura, ulceration and possible renal involvement, and light-chain AL amyloidosis, as well as rare extranodal infiltrates.

The clinical history should investigate not only systemic symptoms such as asthenia, night sweats, weight loss, pruritus and low-grade fever, but also more subtle findings such as distal sensory disturbances, episodes of acrocyanosis or atypical bleeding, which may raise diagnostic suspicion at an early stage. Physical examination should be comprehensive, with assessment for peripheral lymphadenopathy, splenomegaly, signs of hyperviscosity on funduscopic examination, peripheral neuropathy and findings suggestive of extramedullary infiltration.

This broad spectrum of manifestations underscores the need for a vigilant and systematic clinical approach, allowing less typical presentations to be recognized and the most appropriate diagnostic pathway to be initiated promptly.

Investigations and diagnosis

The diagnostic workup of Waldenstrom macroglobulinemia is one of the most complex and delicate aspects of hematologic practice because it requires integration of clinical observation, laboratory testing, morphologic examination, immunophenotyping and genetic studies, with the aim not only of identifying the disease but of distinguishing it unequivocally from all other monoclonal gammopathies and chronic lymphoproliferative disorders.

The workup often begins with nonspecific clinical findings such as anemia, hyperviscosity symptoms, peripheral neuropathy, lymphadenopathy or recurrent infections, or with the incidental detection of a serum monoclonal IgM component during routine testing. Clinical suspicion is then strengthened by serum protein electrophoresis and immunofixation, which document even small amounts of monoclonal IgM. Quantitative measurement of IgM and assessment of the other immunoglobulin classes, often reduced because of polyclonal suppression, provide an initial estimate of disease burden and complication risk.

At the same time, the complete blood count and biochemical profile must be assessed carefully: normocytic anemia, sometimes disproportionate to the degree of marrow infiltration, thrombocytopenia, and abnormalities of erythrocyte sedimentation rate and beta-2-microglobulin are indirect indicators of proliferative activity and bone marrow impairment. Plasma viscosity and renal function are also important for early recognition of hyperviscosity syndromes or autoimmune complications.

The decisive step in diagnosis is bone marrow biopsy, which should be performed whenever an IgM monoclonal gammopathy is suspected. The specimen undergoes morphologic, immunophenotypic and, when necessary, genetic analysis: infiltration by lymphoplasmacytic cells ranging from small lymphocytes to mature plasmacytoid cells is typical. Immunophenotyping, with expression of CD19, CD20, CD22 and CD79a together with plasma-cell markers such as CD38 and CD138 and cytoplasmic monoclonal IgM of kappa or lambda type, identifies the neoplastic clone and helps distinguish it from multiple myeloma, usually CD56-positive and IgG/IgA-producing, and from other non-Hodgkin lymphomas. In many cases cellularity is mixed, with lymphoid infiltration interspersed with plasma-cell foci, making morphology alone potentially challenging.

This phase is complemented by testing for typical genetic mutations. The MYD88 L265P mutation, present in the great majority of cases, supports the diagnosis but is not specific, and its absence does not exclude the disease. CXCR4 mutations have mainly biologic and therapeutic significance.

A fundamental component of the workup is the differential diagnosis. Waldenstrom macroglobulinemia must be distinguished from IgM multiple myeloma, a very rare condition characterized by osteolytic lesions, hypercalcemia, a high proportion of marrow plasma cells and absence of the typical lymphoplasmacytic morphology; from indolent IgM-secreting lymphomas, which show other markers, translocations or specific clinical patterns; and from IgM MGUS, with absent or minimal marrow infiltration and no clinical manifestations or complications.

Imaging studies, including abdominal ultrasound and CT/MRI of the chest, abdomen and pelvis, complete the diagnostic assessment by identifying deep lymphadenopathy, splenomegaly or extramedullary infiltration and are useful for both disease assessment and therapeutic planning. In patients with neurologic signs or cryoglobulinemia, specific investigations may also be required, including cerebrospinal fluid examination, cryoglobulin testing, electromyography and, in selected cases, nerve biopsy.

According to international recommendations (IWG-MRT, WHO), the diagnosis requires the simultaneous presence of the following criteria:

• Serum monoclonal IgM component of any concentration, documented by immunofixation;
• Bone marrow infiltration by lymphoplasmacytic cells, confirmed morphologically and immunophenotypically;
• Absence of morphologic, immunophenotypic or genetic features typical of other lymphoproliferative neoplasms, such as multiple myeloma, mantle cell lymphoma, marginal zone lymphoma, follicular lymphoma and others.

The presence of the MYD88 L265P mutation is highly suggestive and strengthens the diagnosis, but its absence does not exclude the disease. Likewise, the severity of associated complications such as hyperviscosity syndrome, neuropathy and autoimmune phenomena is not part of the diagnostic criteria, although it contributes to disease assessment and therapeutic planning.

Diagnostic evaluation, as well as clinical management, should be entrusted to specialist hematology centers able to integrate all necessary expertise in a multidisciplinary manner and ensure an accurate and timely diagnosis.

Treatment and prognosis

The therapeutic strategy in Waldenstrom macroglobulinemia reflects a careful balance between the need to control neoplastic proliferation, manage complications related to excess IgM and preserve quality of life in a disease that is often chronic and sometimes indolent but potentially progressive. The treatment pathway, now profoundly different from that of the past, is based on rigorous assessment of the indication for therapy, which is not immediate in every patient but is reserved for symptomatic cases or those at risk of severe complications.

The first fundamental decision concerns when to start therapy. In asymptomatic patients with low IgM levels, no cytopenias, limited lymphadenopathy and no hyperviscosity symptoms or neuropathy, a watch-and-wait strategy with periodic clinical and laboratory monitoring is recommended. Observation at this stage does not compromise prognosis and avoids unnecessary toxicity from premature treatment, allowing intervention only when a true clinical need arises.

Active treatment is instead reserved for patients with clinical manifestations attributable to the disease, such as hyperviscosity, symptomatic anemia or thrombocytopenia, symptomatic organomegaly, progressive neuropathy, amyloidosis or cryoglobulinemia; an increase in IgM alone is not sufficient.

In acute hyperviscosity syndrome, emergency treatment is plasma exchange, which rapidly removes IgM from plasma and relieves the most severe symptoms. Plasma exchange has no effect on proliferation of the neoplastic clone and must therefore be followed by initiation of systemic disease-directed therapy.

Systemic treatment is based on immunochemotherapy regimens combining an anti-CD20 monoclonal antibody, mainly rituximab, with conventional chemotherapeutic agents. Regimens may include bendamustine, cyclophosphamide, cladribine, fludarabine or other purine analogues. Common approaches include rituximab-bendamustine or rituximab-cyclophosphamide-dexamethasone (DRC), selected according to clinical and biologic characteristics; purine analogues now have more limited indications because of toxicity.

In recent years, introduction of Bruton tyrosine kinase (BTK) inhibitors, particularly ibrutinib and more recently zanubrutinib, has substantially changed treatment, especially in patients with MYD88 L265P and in refractory or relapsed disease. These orally administered agents can produce durable responses even in older or heavily pretreated patients, with a significant impact on progression-free survival. In patients with CXCR4 mutations or MYD88 wild-type disease, response to BTK inhibitors is less predictable and requires individualized treatment selection.

In selected cases, bortezomib-containing regimens may be used or, in younger patients with relapsed chemosensitive disease, autologous transplantation. Lenalidomide and thalidomide are not standard strategies in Waldenstrom macroglobulinemia because of an unfavorable balance of efficacy and toxicity.

Response monitoring is based on periodic assessment of serum IgM levels, complete blood count, organ function parameters and, when necessary, repeat bone marrow biopsy. Response is defined according to international IWG-MRT criteria, which distinguish complete remission, partial response and stable disease based on disappearance or reduction of the IgM component and marrow infiltration, together with symptom control.

The prognosis of Waldenstrom macroglobulinemia is generally favorable compared with many other hematologic neoplasms, with median survival exceeding 10 years in recent cohorts as a result of therapeutic advances and careful monitoring. Overall and progression-free survival nevertheless depend on several factors, including advanced age, severe anemia, thrombocytopenia, adverse mutations, elevated beta-2-microglobulin and early development of complications such as hyperviscosity, neuropathy or amyloidosis.

In many patients, the disease may remain indolent and controlled for years, with satisfactory quality of life and outpatient management. A minority develop more aggressive or treatment-resistant forms requiring specialist management and access to innovative therapies at referral centers. The risk of transformation to a more aggressive lymphoma is low but should be considered during long-term follow-up.

Optimal management of Waldenstrom macroglobulinemia therefore relies on an individualized approach, multidisciplinary collaboration, integration of hematologic, neurologic and internal medicine expertise, and continuous updating regarding new therapeutic opportunities that continue to improve prognosis and the prospects for long-term disease control.

Complications

The complications of Waldenstrom macroglobulinemia result both from the lymphoplasmacytic proliferation itself and from excessive production of monoclonal IgM. They may involve virtually any organ or function, with severity and clinical impact varying greatly among patients. Early recognition and optimal management of these complications are central components of treatment and follow-up.

One of the most feared complications is hyperviscosity syndrome, which occurs when circulating IgM reaches concentrations sufficient to alter plasma flow properties and impair the microcirculation. Clinical signs include worsening headache, dizziness, visual disturbances such as blurred vision and retinal hemorrhages, tinnitus, confusion and, in severe cases, focal neurologic deficits, seizures and coma. Bleeding manifestations such as epistaxis, gingival bleeding and menorrhagia are common and result from both impaired blood flow and platelet dysfunction, increasing the risk of spontaneous bleeding.

Another important group of complications consists of autoimmune and immune-mediated manifestations. Monoclonal IgM may act as an autoantibody, causing cold agglutinin hemolytic anemia, with jaundice, Raynaud phenomenon and splenomegaly, and occasionally immune thrombocytopenia. Slowly progressive sensorimotor peripheral neuropathy may result either from direct IgM activity against peripheral nerves or from immune-mediated demyelination, with major effects on quality of life and, in advanced cases, loss of functional independence.

Cryoglobulinemia-related complications include Raynaud phenomenon, purpura, skin ulceration, arthralgia and, in more severe cases, membranoproliferative glomerulonephritis with risk of progressive renal failure. In patients with high cryoglobulin levels, exposure to low temperatures may itself precipitate acute manifestations.

A distinct complication is associated AL amyloidosis, which develops when light chains produced by the neoplastic clone deposit in tissues, causing restrictive heart failure, nephrotic syndrome, macroglossia, autonomic neuropathy and potentially severe multiorgan disease. Early diagnosis by biopsy and characterization of the deposited protein is essential to initiate timely, specific treatment.

Infectious complications are also important and are promoted both by impaired immune function, including secondary polyclonal hypogammaglobulinemia, and by the myelosuppressive or immunosuppressive effects of treatment. Bacterial, viral and fungal infections may be severe or fulminant, particularly in patients receiving intensive chemotherapy, monoclonal antibodies or BTK inhibitors.

Over the long term, patients may develop late treatment-related complications, including secondary myelodysplasia, acute leukemia, organ toxicity, particularly cardiac, renal and neurologic, infertility and a mildly increased risk of second primary malignancies. Transformation to aggressive lymphoma is also possible, although rare, and is associated with sudden clinical deterioration, rapid progression and the need for salvage treatment strategies.

Psychological and social complications, often underestimated, include chronic anxiety, depression, stress related to the diagnosis and risk of progression, and functional or social limitations caused by neuropathy, recurrent transfusions or frequent hospital visits. A multidisciplinary approach integrating psychological support and rehabilitation is important to preserve long-term quality of life.

Prevention, early monitoring and proactive management of complications through targeted strategies such as plasma exchange, immunoglobulin therapy, transfusion support, infection prophylaxis and rehabilitation, together with specialist hematologic follow-up, are integral to successful management of Waldenstrom macroglobulinemia.

References
1. Owen RG et al. Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop. Seminars in Oncology. 30, 2, 2003, 110-115.
2. Kastritis E et al. Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 29, Suppl 4, 2018, iv41-iv50.
3. Gertz MA. Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management. American Journal of Hematology. 100, 6, 2025, 1061-1073.
4. Leblond V et al. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood. 128, 10, 2016, 1321-1328.
5. Treon SP et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. New England Journal of Medicine. 367, 9, 2012, 826-833.
6. Tam CS et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 136, 18, 2020, 2038-2050.
7. Castillo JJ et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematology. 7, 11, 2020, e827-e837.
8. Treon SP et al. Report of consensus Panel 4 from the 11th International Workshop on Waldenström's Macroglobulinemia on diagnostic and response criteria. Seminars in Hematology. 60, 2, 2023, 97-106.
9. Gertz MA. Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. American Journal of Hematology. 94, 2, 2019, 266-276.
10. Treon SP et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. New England Journal of Medicine. 372, 15, 2015, 1430-1440.